How to Evaluate De Novo Sequencing Services: Cost Drivers and Vendor Selection

Introduction

Once a research team decides that database-free sequence analysis is necessary, the next challenge is usually commercial rather than technical. How much should a database-free sequencing project cost? What deliverables justify the expense? Which vendor can produce data strong enough for publication, cloning, or QC release? These questions matter because the method is typically more resource-intensive than routine database-assisted identification.

Project cost is shaped by more than sample count. A simple peptide sequencing request and a difficult full-length protein recovery project require different levels of preparation, LC-MS/MS time, assembly effort, and expert review. The same keyword can describe very different scopes of work.

For procurement managers, principal investigators, and quality leaders, the goal is not simply the lowest quote. It is predictable delivery of sequence evidence that supports the next decision. If your team is preparing a budget request or vendor comparison, MtoZ Biolabs can provide a scoped quote based on sample type, coverage target, and reporting requirements.

The Core Selection Question

Before comparing prices, define what the project must prove.

• Is full-length sequence recovery required, or is partial coverage acceptable?

• Will the data support publication, internal QC, cloning design, or vendor qualification?

• Is raw spectral data required for audit or manuscript review?

• Are modifications, truncations, or sequence variants part of the question?

• What turnaround time is required for the next project milestone?

A sequence analysis quote without scope clarity is difficult to compare. Two proposals may differ because one includes only basic sequence reporting, while another includes multi-enzyme digestion, repeat LC-MS/MS, expert assembly, and publication-ready documentation.

Related Services

Customer Need	Recommended Service Direction
Want to confirm purified protein identity	Protein Identification Service
Want to confirm if the N-terminal or C-terminal is correct	N-Terminal Sequencing Service / C-Terminal Sequencing Service
Want to verify recombinant protein sequence coverage	Peptide Mapping Service
No reliable database sequence	De Novo Sequencing Service
Want to analyze truncation, modification, or processing events	Primary Structure Analysis Service

Cost Structure Breakdown

Database-free sequencing project cost usually reflects four components: sample handling, analytical method, data interpretation, and delivery format.

1. Sample-Related Costs

Sample complexity often drives the first cost layer. Purified protein with good integrity and sufficient amount is usually the most straightforward case. Gel bands, low-abundance material, mixed samples, or buffers with interfering components may require additional cleanup, repeat preparation, or feasibility testing.

Factors that commonly increase sample-related cost:

• low protein amount

• poor purity or visible contamination

• difficult buffer composition

• need for additional purification before digestion

• limited sample volume that prevents repeat analysis

2. Method and Instrument Time

The method typically requires LC-MS/MS analysis with enough depth to generate overlapping peptide evidence. Multi-enzyme digestion, repeat runs, fractionation, or extended instrument time can increase cost when the protein is large, modified, or low in abundance.

Method-related cost drivers include:

• protein length and sequence complexity

• number of protease digests

• required LC-MS/MS depth and repeat analysis

• need for additional confirmation experiments

3. Analysis and Expert Review

Unlike routine database searching, database-free sequencing often requires manual review of ambiguous spectra, sequence assembly, and confidence annotation. This expert time is one of the main reasons database-free sequencing is priced differently from standard protein identification.

Analysis-related cost drivers include:

• de novo assembly complexity

• ambiguous or repetitive sequence regions

• PTM or variant annotation needs

• requirement for senior scientist review and sign-off

4. Deliverable and Reporting Requirements

Reporting format can also affect project cost. A basic sequence summary is not equivalent to a publication-ready or QC-ready report with coverage maps, annotated spectra, method description, and raw data delivery.

Delivery-related cost drivers include:

• report template customization

• raw spectral file delivery

• regulatory or QC documentation needs

• rush turnaround or dedicated project management



Figure 1. Request an itemized quote that separates sample, method, analysis, and reporting components.

​

Value Checklist: What a Strong Service Should Include

Price alone is a weak selection criterion. A useful sequencing provider should offer clear value across six areas:

1. Feasibility review before sample shipment

2. Transparent sample requirements and QC checkpoints

3. High-resolution LC-MS/MS capability with documented workflow

4. Expert sequence assembly and confidence annotation

5. Deliverables matched to publication, QC, or development use

6. Responsive project communication and milestone updates



Figure 2. Vendor selection should balance platform capability, QC transparency, and deliverable quality.

​

Typical Timeline and Budget Planning

Turnaround depends on sample quality, protein complexity, and reporting requirements. A straightforward peptide sequencing project may move faster than a full-length protein recovery effort with low sample amount or ambiguous regions.



Figure 3. Confirm milestones and delivery expectations before sample shipment to avoid timeline surprises.

​

Rush services, additional validation, and custom reporting can shorten or extend this schedule. Teams planning around manuscript submission, tech transfer, or batch release should confirm dates before internal deadlines are fixed.

Red Flags to Avoid

When evaluating sequencing providers, watch for these warning signs:

• no feasibility review before sample submission

• unclear sample requirements or missing QC criteria

• quotes that do not explain what is included

• no mention of raw data delivery or coverage evidence

• promise of "full sequence" without sample review

• no path for follow-up validation or partial coverage reporting

• poor responsiveness during scoping discussions

Database-free sequencing is a specialized service. Vague proposals often lead to repeated analysis, missed deadlines, or reports that cannot support the intended use.

When to Add Validation or Related Services

Some projects require more than initial de novo sequence recovery. Budget planning should include follow-up work when the decision standard is high.

Consider adding:

1. N-terminal sequencing or C-terminal sequencing for boundary confirmation

2. Peptide mapping once a reference sequence becomes available

3. Primary structure analysis for biopharmaceutical or QC documentation

4. De Novo Antibody Sequencing Service when the sample is immunoglobulin rather than a general protein

Validation should be planned during scoping, not treated as an unexpected add-on after the first report.

Frequently Asked Questions

1. Why is de novo sequencing more expensive than routine protein identification?

The method requires deeper LC-MS/MS analysis and more expert interpretation because the workflow does not rely on a pre-existing database match.

2. Can I reduce cost by submitting less sample?

Sample requirements vary greatly by project, so please arrange a feasibility review with our technical team first, as insufficient samples may restrict replicate testing, lower data coverage and ultimately raise your total expenditure.

3. Should I ask for raw spectral data?

Yes, if the data will support publication, internal audit, or long-term record keeping. Confirm raw data delivery before project approval.

4. Is the lowest quote the best choice?

Not necessarily. A low quote that excludes QC review, expert assembly, or usable deliverables may cost more when the project must be repeated.

5. Can one provider handle de novo sequencing and follow-up confirmation?

Yes. A provider with broader protein sequence analysis capability can often support de novo recovery, terminal confirmation, and peptide mapping within one project plan.

Conclusion

Evaluating sequencing services requires more than comparing headline prices. Sample complexity, LC-MS/MS depth, expert review, deliverable format, and timeline all influence both cost and success. The best provider is the one that can define scope clearly, review feasibility before sample intake, and deliver sequence evidence that matches the project's decision standard.

For unknown proteins, proprietary sequences, and QC-driven primary structure work, MtoZ Biolabs provides scoped De Novo Sequencing Service proposals with milestone planning, QC documentation, and publication-friendly reporting options. Contact the technical team to request a project assessment and receive a quote aligned with sample type, coverage target, and delivery requirements.